Found vs IVIM Health vs Yucca Health (2026)
On tirzepatide, the order is Yucca Health↗ ($258) → IVIM Health↗ ($278) → Found ($289) — gaps of $20 and then $11 a month, a $372 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The three records, one screen
Yucca Health: the record, condensed
On tirzepatide, the number that matters at Yucca Health is $258 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $258 is the whole subscription, which makes Yucca Health unusually easy to compare and unusually easy to leave.
To place the number: #2 of 17 verified programs, with the floor $43/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $191 a month. A year at this figure: $3,096 monthly-billed.
On semaglutide, the number that matters at Yucca Health is $146 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Yucca Health is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $146 is the whole subscription, which makes Yucca Health unusually easy to compare and unusually easy to leave.
Context for that figure: it ranks #2 of 20 in the verified semaglutide index — $13/month above the floor (Oak Longevity, $133) — and sits $203 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,752.
Operationally at Yucca Health: shipping included; commitment 6-month term; cancellation 6-month term applies; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Yucca Health page · visit Yucca Health ↗
IVIM Health: the record, condensed
IVIM Health’s tirzepatide program bills $278 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Pricing steps with the dose here: from $208 at entry to $278 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $840 a year, which is why every ranking on this site uses the larger number.
The all-in figure already contains a compulsory $75 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $203 would be exactly that kind of mirage.
To place the number: #3 of 17 verified programs, with the floor $63/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $171 a month. A year at this figure: $3,336 monthly-billed.
IVIM Health’s semaglutide program bills $149 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.
Inside that $149 sits a mandatory $75-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $74, and it is not a price anyone can actually pay, because the membership cannot be declined.
Context for that figure: it ranks #3 of 20 in the verified semaglutide index — $16/month above the floor (Oak Longevity, $133) — and sits $200 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $1,788.
Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗
Found: the record, condensed
Found’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Found is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes Found unusually easy to compare and unusually easy to leave.
To place the number: #6 of 17 verified programs, with the floor $74/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.
Found’s semaglutide program bills $289 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes Found unusually easy to compare and unusually easy to leave.
Context for that figure: it ranks #15 of 20 in the verified semaglutide index — $156/month above the floor (Oak Longevity, $133) — and sits $60 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,468.
Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗
Prices, gaps, and what sits inside them
Yucca Health holds the low ground at $258 — dose-flat, so that figure is a ceiling with no membership attached. IVIM Health follows at $278 (+$20/mo, $240/yr), membership included. Found tops the trio at $289 (+$31/mo over the leader, $372/yr) — note its record’s watch-out below.
The semaglutide picture reshuffles nothing: Yucca Health $146 → IVIM Health $149 → Found $289 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.
Who wins what
Cheapest month-to-month: Yucca Health ($258); cheapest 12-month path: Yucca Health ($3,096); simplest billing (no membership): Yucca Health and Found; dose-flat structure: Yucca Health and Found; cheapest semaglutide of the three: Yucca Health ($146).
Every winner above is a computation, not a placement; the pairwise pages carry the full duels: Yucca Health vs IVIM Health · Yucca Health vs Found · IVIM Health vs Found.
Everything besides the three prices
Memberships: Yucca Health none; IVIM Health $75/mo (inside its figure); Found none. Structures: Yucca Health dose-flat; IVIM Health step/tiered; Found dose-flat. Pharmacies: Yucca Health not named; IVIM Health not named; Found not named. States: Yucca Health — not published; IVIM Health — not published; Found — most states. Exit terms: Yucca Health — 6-month term applies; IVIM Health — membership mandatory; Found — membership recurs; prepaid terms are paid up front.
The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: Yucca Health source-verified (2026-08-05); IVIM Health source-verified (2026-08-05); Found third-party reported (2026-08-05).
The trio on semaglutide, across time
3 mo: Yucca Health $438 vs IVIM Health $447 vs Found $867 6 mo: Yucca Health $876 vs IVIM Health $894 vs Found $1,734 12 mo: Yucca Health $1,752 vs IVIM Health $1,788 vs Found $3,468 — monthly-billed totals; prepaid paths where published appear on each provider page.
The trio, annualized
Yucca Health: $3,096/yr monthly-billed; IVIM Health: $3,336/yr monthly-billed; Found: $3,468/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $744 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.
The elimination read
A three-way choice is really two eliminations, so run them in order. Eliminate Found first unless it names its edge: at $289 it carries a $31/month premium over the floor of this trio — $372 a year, about 1.4 extra months of therapy at Yucca Health’s rate — and a premium that size must point at a specific line in its record (its insurance navigation) or it is decoration. Then interrogate IVIM Health’s middle ground: its $75/mo membership bundles services the floor does not; if that specific thing is on your personal ledger, the $20/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is Yucca Health at $258, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.
The same trio on best published rate: Yucca Health $258 → IVIM Health $278 → Found $289 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — Yucca Health $774, IVIM Health $834, Found $867; 6 months — Yucca Health $1,548, IVIM Health $1,668, Found $1,734. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.
The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): Yucca Health 4/5, IVIM Health 4/5, Found 3/5. Yucca Health discloses the most and Found the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. The three match on every disclosure axis, which is rare and worth noting in their favor collectively. Scores recompute from the public records like everything else here.
Read as a decision: start from Yucca Health and make the other two argue upward. IVIM Health’s case is its structure; Found’s case must be worth $372 a year in named features — the honest unit being months of medication (1.4 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.
Frequently asked
Which is cheapest: Found, IVIM Health, or Yucca Health?
Yucca Health, at $258/month all-in tirzepatide — $20 under IVIM Health and $31 under Found; on semaglutide the cheapest of the three is Yucca Health at $146. Captured 2026-08-09.
Which of the three is best over a full year?
Yucca Health’s best path prices twelve months at $3,096; monthly-billed years run Yucca Health $3,096, IVIM Health $3,336, Found $3,468.
Are these rankings paid or editorial?
Neither — they are sorts of the public dataset on the all-in maintenance basis, regenerated on every data change; the methodology page defines the basis and the JSON lets you recompute every figure here.